Introduction
In recent years, clinical trials of stem cell therapies for neurological disorders have begun. Specifically in multiple sclerosis (MS), a number of trials studying the potential of bonemarrow-derived stem cell therapies have been published [1] [2] [3] . The initial experimental rationale was to regard stem cells as multipotential cells capable of differentiating into central nervous system cells able to replace lost or damaged cells in diseased tissue. Indeed, major research programmes of myelin repair are ongoing [4] . A further, and potentially more clinically applicable, function of stem cells is their ability to modulate disease processes. Mesenchymal stem cells (MSCs) have potent immune modulatory effects in experimental models [5] . Furthermore, MSCs are able to secrete a variety of substances that may attenuate disease processes or provide trophic support for the diseased nervous system [6, 7] . In MS, oxidative stress is associated with significant damage to myelin and axons, which in turn leads to clinical symptoms [8] . A major research strategy for many years has been to develop therapies which reduce the damage caused by oxidative stress and thus reduce tissue injury. This paper will focus on stem cells, and specifically MSCs, as providers of antioxidant function for central nervous system cells.
immunological interplay in MS is much more complicated than first thought. Evidence countering the central role for CD4 + T cells includes the fact that MHC class 1-restricted CD8 + cells are the predominant cell type found in active MS lesions [13] ; lymphocytes may not be present in early demyelinating lesions and perivascular inflammatory cuffs can occur in normal appearing white matter [14] . In addition, therapies such as anti-interleukin 12p40 that target CD4 + T-cell function have proved ineffective in clinical trials [15] . These and other developments have led to the need for further interrogation of the underlying immunology of the condition and redirected efforts to focus on alternative cell types that may contribute to the pathogenesis of MS. Previously, unknown contributors to the disease process include Th17 cells (producing IL 17), B cells, CD8 + cells, and both CD4 + and CD8 + T-regulatory cells. Other effector populations include CD56 + natural killer cells, invariant NK cells, and stem cells [16] . There is also evidence for the role of humoral immunity in MS demonstrated by the presence of immunoglobulin on macrophages actively phagocytosing myelin [17] , immunoglobulin and complement in degenerating myelin sheaths [18] , and by the occurrence of plasma cells in plaques [19] .
Patterns of Tissue Injury in MS and Experimental
Demyelinating Models. Pathological changes noted in postmortem or (more rarely) biopsy tissue from patients suffering from MS have revealed some of the mechanisms of tissue damage. Several patterns of tissue injury have been demonstrated. Although only able to offer a "snap shot" of tissue damage, certain common themes, some specifically relating to oxidative damage, have emerged.
(i) Classical Actively Demyelinating Lesions. There is a broad spectrum of immunological findings with some lesions dominated by T cells and macrophages, whilst others are notable for their immunoglobulin and complement components. Experimental demyelinating lesions can be induced by cytotoxic T cells, autoantibody generation, and genetic abnormalities giving further indications of the variety of factors that may determine an in vivo lesion [20] . In EAE, inoculation with myelin components, including myelin basic protein (MBP), proteolipoprotein, myelin oligodendrocyte glycoprotein, myelinassociated glycoprotein, and S100 protein, elicits an immunological response mediated via CD4 + MBPreactive T cells resulting in paralytic signs in the host organism. In EAE, demyelinating lesions require the presence of T cells, myelin autoantibodies, and complement activation though the relevance of this observation to MS is not fully established [21] . (ii) Slowly Expanding Lesions of Progressive MS. These are notable for the presence of a rim of activated microglia at their periphery with associated active demyelination. Macrophages containing myelin degradation products are not found within these lesions. T-cell infiltrates are located perivascularly but are not prevalent [22] .
(iii) Cortical Demyelination. Cortical lesions are most commonly found in the deep sulcal structures in band-like subpial lesions [23] . Within these lesions, profound microglial activation can be viewed largely in the absence of lymphocytes [24] . The presence of a multitude of inflammatory cells within the meninges overlying these lesions has led some to hypothesise that they are driven by soluble factors released by the overlying cells [20] .
(iv) Diffuse White Matter Injury. The so called "normal appearing white matter" (NAWM) (defined on magnetic resonance imaging) in fact demonstrates pathological abnormalities in MS patients, particularly in the progressive stages of the disease [25] . There is a predominance of CD8 + MHC class I-restricted T lymphocytes in a diffuse inflammatory infiltrate found particularly in the perivascular space. There is widespread activation of microglia expressing footprint activation antigens of radical production, and microglial activation is closely associated with diffuse axonal injury/loss. There is no doubt that some Wallerian degeneration of axons occurs following focal demyelinating lesions, but within the NAWM there is a greater degree of inflammation and microglial activation than would be expected with Wallerian degeneration alone [20] . Many of the mechanisms leading to diffuse injury in NAWM are poorly understood; within activated microglia, frequently found in NAWM, there is expression of type-II nitric oxide synthases suggesting that oxygen and nitric oxide radicals are involved in the process; nitric oxide/oxygen free radicals inhibit enzymes of the respiratory chain causing mitochondrial dysfunction [26] which may be an important factor driving axon dysfunction; the size-dependent axonal loss in NAWM suggests energy deficiency which may also play an important role in the progressive axon loss characterising the latter stages of the disease [27] .
Oxidative and Nitrative Stress.
Reactive oxygen species (ROS) and reactive nitrogen species (RNS) are generated as part of normal cellular physiology. However, if there is overproduction of ROS or a failure of antioxidant mechanisms, these species can cause damage to lipids, proteins, and nucleic acids and may lead to cell death. CNS neurones are constantly exposed to low levels of these oxidative/nitrative species which can easily be dealt with by inherent repair and protection mechanisms. In the inflammatory state, however, these defences can become overwhelmed leading to oxidative/nitrative stress and damage to the basic structural and functional elements of the cells. Reactive oxygen and nitrogen species include superoxide ions, hydrogen peroxide, nitric oxide, and peroxynitrite, all of which are produced as part of the inflammatory response and have a potential role in tissue damage in multiple sclerosis. There are several reasons why the CNS is particularly vulnerable to oxidative damage. These include the fact that brain tissue is very active in oxidative metabolism leading to relatively high levels of intracellular superoxides: the limited ability of the CNS to engage in anaerobic respiration resulting in high levels of superoxides in a hypoxic environment [29] ; cellular features predisposing to oxidative damage within the oligodendrocyte population including low levels of antioxidant defences, membrane elaborations, and high iron content; the composition of myelin as a preferential target of ROS due to high protein : lipid ratio [30] .
Reactive Nitrogen Species.
Nitric oxide (NO) is produced in the nervous system in response to inflammation through the induction of inflammatory nitric oxide synthase (iNOS). It has been demonstrated that there is increased iNOS production, and by implication NO species, in the CNS of animals with EAE, [31] . There is also evidence of increased proinflammatory cytokine production in MS, and by extension NO [9] . Further indirect evidence of NO production includes the following: TNFα and IFNγ have been identified in astrocytes within both CNS lesions and CSF white blood cells of patients with MS [32] ; higher levels of NO have been demonstrated within the peripheral monocytes of patients with MS compared with control subjects [33] ; nitrite and nitrate levels are elevated in the CSF of patients with MS [34] . Direct evidence includes the fact that iNOS mRNA has been identified in MS plaques [35] with evidence that macrophages, astrocytes, and microglia within active lesions express high levels of iNOS and endothelial NOS [36] . There is also evidence for the presence of reactive nitrogen species in MS through nitrotyrosine, a marker of the presence of peroxynitrite, which is found in the diseased brain particularly in areas of demyelination and inflammation [37] .
Reactive nitrogen species have a wide variety of effects on cells through the modification of protein structure and function: they inhibit several enzymes involved in respiration thereby disrupting mitochondrial function and reducing ATP content as demonstrated in neurons exposed to NO [32] ; NO is known to affect several of the enzymes involved in oxidative defence including catalase [38] ; it has been hypothesised that oxidation also results in the production of epitopes which may provoke autoimmune responses [39] ; peroxynitrite can lead to cell death through a number of mechanisms including affecting cell signalling and through DNA breakdown [40] ; NO can also deaminate DNA [41] and inhibit repair mechanisms [42] . Both reactive nitrogen and oxygen species also affect lipid peroxidation and consequently membrane function/permeability, which has implications for the function of embedded proteins within the lipid bilayer [43] .
Oligodendrocytes show particular susceptibility to NO species and can even be lysed by the levels of NO produced by activated microglial cells. Experiments have shown that this lysis can be prevented in coculture by the addition of antagonists of NO production [44] .
High levels of phosphorylation within axon neurofilaments protect against proteolysis. Dephosphorylation renders the axons more susceptible to proteolytic damage and axonal degeneration [45] . It has been shown that inflammatory agents, such as nitric oxide (NO), reduce neurofilament phosphorylation levels and thereby facilitate axon destruction. It is also known that inflammation causes conduction block and has been demonstrated in vivo that NO/derivatives can block conduction in both central and peripheral axons and that demyelinated axons are particularly vulnerable to NO-mediated block [46] .
Reactive Oxygen Species.
Extensive evidence implies increased ROS production in inflammatory demyelinating diseases. Human microglia are one of the most potent producers of superoxide [47] , and it is known that during inflammatory demyelinating disease cells such as these are recruited to lesions within the CNS. Neurons also produce ROS in response to electrical activity following eicosanoid production driven by calcium cellular influx [48] . Direct evidence of lipid peroxidation has been demonstrated in postmortem brain tissue with findings pointing to a pivotal role in early plaque evolution [49] . There is also evidence for increased ROS production in EAE with macrophages and microglial cells exhibiting high levels compared with controls [50] and for higher levels of superoxide throughout affected brain areas [51] . It has also been noted that peroxynitrite is formed very early in the course of EAE and correlates with disease activity [52] .
Oligodendrocytes are susceptible experimentally to ROSmediated damage at levels which do not affect astrocytes or macrophages [53] . The high levels of iron found in oligodendrocytes, reacting with hydrogen peroxide and leading to the formation of the highly toxic peroxynitrite, may explain this susceptibility. In addition, low oligodendrocyte levels of glutathione, the failure of expression of Mn-SOD, and low levels of metallothionein, all important antioxidants, may contribute [54] [55] [56] . Hydrogen peroxide is produced in peroxisomes which are particularly abundant in oligodendrocytes during the period of active remyelination, contributing to the failure of long-term repair of myelin and the axon loss associated with the progressive stages of the disease. Furthermore, preoligodendrocytes appear to be significantly more sensitive to oxidative stress compared to mature oligodendroctes [57] providing further barriers to repair and remyelination. ROS also have direct effects on the lipid and protein components of myelin, directly through peroxidation and indirectly through the production of matrix metalloproteinases which have been shown to degrade myelin basic protein.
Detoxification of Reactive Oxygen and Nitrogen Species.
Cells possess a diverse array of defence mechanisms to reduce potentially harmful build-up of ROS, specifically a number of antioxidant enzymes including superoxide dismutase, catalase, glutathione peroxidase, and glutathione reductase ( Figure 1 ). The balance between ROS/RNS and detoxifying enzymes within inflamed tissue may be crucially important in determining the extent of cellular damage and tissue injury. The cause of axonal degeneration in secondary progressive disease is unknown, but recent evidence has suggested a role for central nervous system peroxisomes in axonal maintenance [58] . Peroxisomes are cellular organelles which are involved in a number of anabolic and catabolic reactions and may have an important role in the detoxification of inflammatory compounds such as ROS. Both SOD and catalase are produced by peroxisomes, and catalase is specific to peroxisomes. Inherited abnormalities in peroxisomal function cause a variety of neurological disorders, including X-linked adrenoleucodystrophy and adrenomyeloneuropathy, which share many clinical, radiological, and neuropathological features with multiple sclerosis [59] . Furthermore, defects in peroxisomal function within the central nervous Autoimmune Diseases 5 system have been implicated in experimental models of neuroinflammatory and neurodegenerative disease [60] . Thus, peroxisomes may have vital functions in multiple sclerosis of limiting tissue damage. We have previously shown that nitric oxide causes significant axonal and neuronal damage in cell culture models (Figure 3 ) [61] and that the addition of recombinant SOD to cultures protects cerebellar neurons from nitric-oxide-mediated injury [62, 63] .
Cell-Based Approaches to Combat Oxidative Damage in Multiple Sclerosis
A number of different cell-based approaches to repair and protect against tissue damage in MS have been postulated and are the subject of intense research. Examples include haematopoietic stem cells which have been used in an immune-reprogramming capacity and neural stem cells which are predominantly being explored for their regenerative potential. Meanwhile, mesenchymal stem cells (MSCs) (Figure 2 ) have emerged as promising candidates in the protection of neurones against the oxidative damage encountered in MS. Here we describe the biology of MSCs and the antioxidant properties which may have future relevance to the treatment of the disease.
Mesenchymal Stem Cells.
The potential therapeutic applications of MSCs for neurological disorders have generated great interest. To date, human MSC transplantation has been shown to improve outcome in a variety of animal models of neurological disease including that of experimental autoimmune encephalomyelitis, stroke, amyotrophic lateral sclerosis, Krabbe's disease, and spinal cord injury [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] . Pilot translational studies of MSC therapy have also commenced in stroke [78] , multiple system atrophy [79] , amyotrophic lateral sclerosis [80] , metachromatic leukodystrophy, and Hurlers syndrome [81] , as well as in multiple sclerosis [82] . Administration of MSC is an attractive therapeutic option in these disorders as MSCs are easily isolated from various anatomical sources, have versatile growth and differentiation potential, and their immunosuppressive properties make it probable that allogeneic as well as autologous cell therapy could be considered. This is of importance since in clinical therapies the use of an allogeneic source for cellular therapy is likely to be more convenient and feasible than an autologous population which would take weeks to prepare [83] . Despite having a favourable safety profile in comparison with some other types of stem cells, there are undoubtedly risks associated with MSC treatments which should not go unexplored. The use of an allogenic MSC bank, for example, would carry with it the risks of chromosomal abnormalities associated with longterm cell culture and development of therapies will require the provision of careful and considered safety studies and protocols. MSCs were first identified in 1966 in studies by Friedenstein et al., who isolated bone-/cartilage-forming progenitor cells from rat bone marrow cells with fibroblast-like morphology [84] . Since this discovery, the most studied and accessible source of MSCs has been the bone marrow, although MSCs have been isolated from a number of tissues including the liver, foetal blood, cord blood, and amniotic fluid [85] [86] [87] [88] [89] [90] [91] [92] [93] . Unlike the haematopoietic stem cells and their progeny, cultured MSCs express a number of nonspecific surface markers, none of which, individually or in combination, have been shown to achieve high levels of MSC isolation and enrichment [94] [95] [96] [97] [98] . Within the bone marrow, MSCs comprise 0.001-0.1% of the total population of nucleated cells [85] . MSCs may be considered multi-potent stem cells that have the ability to differentiate down both mesenchymal and nonmesenchymal lineages. Human MSCs contribute to the regeneration of mesenchymal tissues such as bone, cartilage, muscle, ligament, tendon, adipose, and stroma [85] and can also give rise to cells with ectodermal and endodermal phenotypes [98] [99] [100] [101] [102] [103] [104] .
Research suggests that transplantation of MSCs has the potential to be an effective treatment for neurodegenerative disorders through a multitude of different mechanisms including replacement of lost cells by differentiation into functional neural tissue, modulation of the immune system to prevent further neurodegeneration, and provision of trophic support for the diseased nervous system [105] . Bone-marrow-derived MSCs are able to evade the allogeneic immune system, as well as suppress immune responses directed against third-party cells following intravenous infusion [106] [107] [108] [109] . In addition, when infused into the circulation, MSCs have the capacity to migrate specifically to sites of brain injury, thus targeting sites for neural repair [75] [76] [77] . Although MSCs display a plethora of neuroprotective and regenerative properties, increasing evidence implies that the major mechanistic neuroprotective role of bone-marrowderived MSCs is their capacity to secrete a diverse range of potentially neuroprotective factors including antioxidants [5, 6, 105, [110] [111] [112] . With many antioxidant drugs emerging as potential therapeutic agents for neurodegenerative disorders [113, 114] , these findings emphasise the potential for bone-marrow-derived MSCs as therapeutic agents for CNS neurodegenerative disorders, especially disorders in which oxidative damage is a key aetiological component.
Antioxidant Properties of Mesenchymal Stem Cells.
MSCs have direct antioxidant activity that is conducive to neuroprotection both in vivo and in vitro [5, 7] . In vitro studies have shown that MSC-conditioned media can confer a neuroprotective effect against oxidative insult to both primary cortical and cerebellar neurons, and also neuroblastoma cell lines [5] [6] [7] 63] . Evidence suggests that one method by which MSCs exert a neuroprotective effect against oxidative stress is through the modulation of signalling pathways involved in antioxidant and stress-related processes. Nitric oxide, whilst performing many physiological roles at low levels, has been shown to induce apoptosis in a variety of cultured peripheral and central neurons and be involved in degeneration during central nervous system inflammation [115, 116] . It has been established that these effects are mediated through the p38 MAP kinase pathway [61] . Secreted protein factors, including neurotrophic factors and cytokines, are thought to have the ability to inhibit death-inducing pathways and also activate cell survival pathways [117, 118] . MSCs have been shown to protect neurons against toxic insults via modulation of both the PI 3 kinase/Akt and MAP kinase pathways [7] .
Another mechanism by which MSCs can exert a direct antioxidant effect is through the secretion of antioxidant molecules. We have recently shown that bone-marrowderived MSCs secrete the extracellular antioxidant molecule superoxide dismutase 3 (SOD3) [7, 63] . The superoxide dismutase family member SOD3 is the only antioxidant enzyme that scavenges superoxide in the extracellular compartment [119] and limits the formation of strong neurotoxic oxidants including both the hydroxyl radical and peroxynitrite in the extracellular space. It has been demonstrated in a variety of studies that SOD3 can attenuate tissue damage and inflammation [120] [121] [122] [123] [124] [125] [126] [127] [128] ; in addition, SOD3 secretion by human MSCs has been shown to provide direct neuroprotection in cerebellar neurons exposed to nitric oxide and activated microglia [7, 63] . Experiments show that SOD3 secretion by human bone-marrow-derived MSCs is regulated synergistically by the inflammatory cytokines TNFα and IFNγ [63] . Both TNFα and IFNγ are important mediators of the immune system and inflammatory processes in the CNS and are therefore present in the diseased brain. In EAE and other central nervous system inflammatory disorders, both IFNγ and TNFα are upregulated and are critically involved in the initiation and amplification of the local immune response [129] . These cytokines also enhance the secretion of the superoxide ions by a variety of immune and nonimmune cells [130] [131] [132] [133] . In summary, SOD3 secretion by MSCs is a potentially valuable and regulatable therapeutic antiinflammatory property that may be of relevance to treatment strategies for inflammatory disease of the CNS.
Several studies have looked at the effects of transplanted MSCs on both the clinical course and immunopathology of EAE. MSC transplantation confers significant therapeutic capacity to modulate autoimmune processes, resulting in significant reductions in demyelination and lesion size within the CNS and also reductions in the number of cellular infiltrates in the brains of the host organism [68, 69, [134] [135] [136] [137] . Inflammatory processes within the CNS involve activated microglia, astrocytes, macrophages, and lymphocytes, releasing a plethora of anti-and proinflammatory cytokines [138] . Evidence from both in vitro and in vivo studies suggests that MSCs have the ability to inhibit microglial activation and therefore attenuate inflammation [139] [140] [141] [142] . It has also been shown that MSCs are capable of significantly decreasing inducible nitric oxide synthase (iNOS) expression within microglia [140] , thus enhancing their antioxidative effect. Further supporting evidence has recently shown that MSCs inhibit molecules associated with neuronal damage and display a variety of antioxidant effects when administered to EAE mice [5] .
Conclusions
MSCs possess a diverse range of properties making them attractive candidates for cell-based therapies. In particular, antioxidant functions may be utilised as a strategy to reduce inflammation-driven oxidative stress. Cell-based therapies for MS are currently in development, and the diverse modes of action of stem cells make them attractive candidates. Further work to enhance delivery and targeting of cells, plus optimising and regulating their antioxidant properties, is required, but stem cell therapies for MS may form an important part of the therapeutic armoury for the disease in years to come.
